勃林格殷格翰的思力华可治疗什么疾病？

(Repimat) contains tiotropium bromide, a new environmentally friendly long-acting inhaled anticholinergic drug that interacts with β2 adrenoceptor agonists to keep the patient's airways open for 24 hours, selectively blocks the M1 and M3 receptors of airway smooth muscle, relaxes the contracted bronchial smooth muscle, promotes drug deposition in the lungs to about 50%, and exerts a powerful and lasting bronchodilator effect. A domestic study found that the combination of Seriva and Seretide was used to treat adult patients with chronic obstructive pulmonary disease (COPD) with a short course of treatment, a low recurrence rate, a low total cost, and the combined effect of the two drugs was relatively good.

In order to observe and evaluate the clinical effect of Seretide combined with Serivata in the treatment of pulmonary function in patients with stable chronic obstructive pulmonary disease (COPD), a domestic study conducted 86 patients with stable COPD who were randomly divided into two groups according to the numerical method; 43 patients in the control group were treated with Seretide, and 43 patients in the observation group were treated with Serivata in addition to the control group, and the clinical effects of the two groups were compared.

Results: The total effective rate of the observation group was 97.67%, which was significantly higher than the 86.05% of the control group; PaO2 of both groups after treatment was significantly higher than before treatment, while PaCO2 was significantly lower than before treatment. PaO2 of the observation group was significantly higher than that of the control group, and PaCO2 of the observation group was significantly lower than that of the control group; FEV1, FVC, and FEV1/FVC of both groups after treatment were significantly higher than before treatment, and FEV1, FVC, and FEV1/FVC of the observation group were higher than those of the control group.

Boehringer Ingelheim has always adhered to the tradition of "innovation demonstrates value and R&D drives growth", and has finally extended from the Rhine River in Germany to more than 40 countries and regions around the world. The combination of seretide developed by it to treat COPD patients can effectively improve the clinical efficacy and significantly improve clinical symptoms and lung function, and is worthy of vigorous clinical promotion.

Recommended hot articles: /newsDetail/94275.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.